Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.46 |
| ▸ | HRAS | P01112 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980624 | 0.96 | MAPK1 (0.52) | LMNASMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL20985069 | 0.94 | MAPK1 (0.53) | LMNASMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL24294654 | 0.93 | LMNA (0.50) | LMNASMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL26634406 | 0.91 | LMNA (0.50) | LMNASMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL24699869 | 0.91 | MAPK1 (0.57) | MEN1KMT2AMAPK1B4GALT1HRAS | |
| SCHEMBL22855653 | 0.91 | MAPK1 (0.57) | MEN1KMT2AMAPK1B4GALT1HRAS | |
| SCHEMBL17283441 | 0.89 | MAPK1 (0.60) | MEN1KMT2AMAPK1B4GALT1HRAS | |
| SCHEMBL2003046 | 0.88 | LMNA (0.50) | LMNASMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL31536702 | 0.86 | EPOR (0.43) | LMNASMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL24294564 | 0.85 | LMNA (0.47) | LMNASMN1; SMN2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ERBB2, PCNA, MRE11 | LMNA 1950/4885SMN1; SMN2 1422/4885MEN1 1835/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | LMNA 64/4885SMN1; SMN2 358/4885MEN1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.